<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OPP</journal-id>
<journal-id journal-id-type="hwp">spopp</journal-id>
<journal-id journal-id-type="nlm-ta">J Oncol Pharm Pract</journal-id>
<journal-title>Journal of Oncology Pharmacy Practice</journal-title>
<issn pub-type="ppub">1078-1552</issn>
<issn pub-type="epub">1477-092X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1078155212461289</article-id>
<article-id pub-id-type="publisher-id">10.1177_1078155212461289</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Paronychia induced by the epidermal growth factor receptor inhibitor cetuximab</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname><given-names>Soo Lin</given-names></name>
<xref ref-type="corresp" rid="corresp1-1078155212461289"/>
</contrib>
<aff id="aff1-1078155212461289">Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Tan</surname><given-names>Boon Seang</given-names></name>
</contrib>
<aff id="aff2-1078155212461289">Department of Oncology and Radiotherapy, Hospital Pulau Pinang, Malaysia</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chan</surname><given-names>Lee Chin</given-names></name>
</contrib>
<aff id="aff3-1078155212461289">Department of Dermatology, Hospital Pulau Pinang, Malaysia</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1078155212461289">Soo Lin Lee, Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia. Email: <email>lee.gsl@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>273</fpage>
<lpage>278</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>While the development of epidermal growth factor receptor inhibitors has been hailed as a remarkable triumph in the field of oncology, it has inherited with it a host of cutaneous side-effects that have been increasingly observed in a substantial number of patients in the recent years. One cutaneous manifestation that may inflict significant pain and affect activities of daily living among some of the patients receiving epidermal growth factor receptor inhibitors is paronychia. A case of paronychia associated with the use of cetuximab in the management of KRAS wild-type midrectal adenocarcinoma along with its management has been described.</p>
</abstract>
<kwd-group>
<kwd>Cetuximab</kwd>
<kwd>epidermal growth factor inhibitor</kwd>
<kwd>monoclonal antibody</kwd>
<kwd>metastatic colorectal cancer</kwd>
<kwd>paronychia</kwd>
<kwd>periungual granulation</kwd>
<kwd>cutaneous reactions</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein of the tyrosine kinase growth factor family that is expressed in many normal human tissues.<sup><xref ref-type="bibr" rid="bibr1-1078155212461289">1</xref><xref ref-type="bibr" rid="bibr2-1078155212461289"/>–<xref ref-type="bibr" rid="bibr3-1078155212461289">3</xref></sup> It is finely regulated to control cell growth and proliferation. However, in solid tumour malignancies such as colorectal, lung, head and neck carcinomas, there will be dysregulation and overexpression of the receptors that translates into increased metastasis, reduced survival and a poor prognosis.<sup><xref ref-type="bibr" rid="bibr3-1078155212461289">3</xref></sup> Thus, controlling the aberrant signalling by means of selective EGFR inhibition is anticipated to inhibit tumour growth without incurring many side-effects that are commonly associated with the use of conventional chemotherapeutic agents.<sup><xref ref-type="bibr" rid="bibr1-1078155212461289">1</xref></sup> This has led to the development of agents targeting EGFR such as monoclonal antibodies (cetuximab and panitumumab) against the extracelullar ligand-binding domain of the receptor and small-molecule tyrosine-kinase inhibitors (erlotinib, gefitinib), which block the signal-transduction cascade by competing with adenosine triphosphate for binding to the tyrosine-kinase domain.<sup><xref ref-type="bibr" rid="bibr1-1078155212461289">1</xref></sup></p>
<p>Cetuximab is an intravenously administered chimeric human/murine monoclonal antibody that was granted accelerated approval by the FDA in 2004 for the treatment of metastatic colorectal carcinoma.<sup><xref ref-type="bibr" rid="bibr4-1078155212461289">4</xref></sup> In CRYSTAL trial, cetuximab has shown to increase the activity of a cytotoxic doublet in the first-line treatment in KRAS wild-type patients. A survival, progression-free survival and response rate advantage has been demonstrated for the combination FOLFIRI/cetuximab compared with FOLFIRI alone in the first-line treatment of KRAS wild-type patients.<sup><xref ref-type="bibr" rid="bibr5-1078155212461289">5</xref>,<xref ref-type="bibr" rid="bibr6-1078155212461289">6</xref></sup> As such, cetuximab has been increasingly utilized for cases in which it is indicated in the recent years. This report presents a case of paronychia with periungual granulation which is a cutaneous adverse effect of treatment with cetuximab.</p>
<sec id="sec1-1078155212461289" sec-type="cases"><title>Case report</title>
<p>YKB, a 43-year-old Chinese lady, was diagnosed as having KRAS wild-type midrectal adenocarcinoma with lymph node metastases. She was electively admitted for her eighth cycle of FOLFIRI and fourth cycle of cetuximab palliative chemotherapy (see <xref ref-type="table" rid="table1-1078155212461289">Table 1</xref> for dosing regimen) when she presented with bilateral multiple hypertrophied nailbeds with erythematous skin lesion over all the fingers on both hands as depicted in <xref ref-type="fig" rid="fig1-1078155212461289">Figure 1(a)</xref> and skin dryness throughout her body. Symptoms developed 6 weeks after the initiation of cetuximab. Other history of illness includes delayed severe diarrhoea and mild vomiting following her seventh cycle of chemotherapy that translated into hospitalization thereafter for immediate rehydration (see <xref ref-type="table" rid="table2-1078155212461289">Table 2</xref> for sequence of adverse events). Her past medical history includes cervical cancer by which total abdominal hysterectomy bilateral salpingo-oophorectomy (TAHBSO) was performed, resolved left Bell’s palsy and duodenum carcinoma (T<sub>3</sub>N<sub>0</sub>) treated with adjuvant XELOX and Whipple’s procedure. She, too, had anterior resection done when she was diagnosed with the current disease. She has very strong family history of cancer, of whom four of her siblings were diagnosed as having colon cancer.
<fig id="fig1-1078155212461289" position="float"><label>Figure 1.</label><caption><p>Paronychial inflammation with pyogenic-like lesions over the fingers of both hands in the patient who received cetuximab.</p></caption><graphic xlink:href="10.1177_1078155212461289-fig1.tif"/>
</fig>
<table-wrap id="table1-1078155212461289" position="float"><label>Table 1.</label><caption><p>Cetuximab-FOLFIRI chemotherapy regimen.</p></caption>
<graphic alternate-form-of="table1-1078155212461289" xlink:href="10.1177_1078155212461289-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Drug</th>
<th>Dose (mg/m<sup>2</sup>)</th>
<th>Dose (mg)</th>
<th>Day</th>
<th>Dosing interval</th></tr></thead>
<tbody align="left">
<tr>
<td>Cetuximab</td>
<td>500</td>
<td>400</td>
<td>D1</td>
<td>2 weekly</td></tr>
<tr>
<td><bold>FOLFIRI</bold></td>
<td colspan="2"/>
<td/>
<td/></tr>
<tr>
<td>Irinotecan</td>
<td>180</td>
<td>160</td>
<td>D1</td>
<td>2 weekly</td></tr>
<tr>
<td>Folinic Acid</td>
<td>200</td>
<td>216</td>
<td>D1-2</td>
<td>2 weekly</td></tr>
<tr>
<td>5-Fluorouracil</td>
<td>400</td>
<td>425</td>
<td>D1-2</td>
<td>2 weekly</td></tr>
<tr>
<td>5-Fluorouracil</td>
<td>600</td>
<td>650</td>
<td>D1-2</td>
<td>2 weekly</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1078155212461289"><p>D: day.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1078155212461289" position="float"><label>Table 2.</label><caption><p>Sequence of adverse events that occurred following the administration of FOLFIRI-Cetuximab chemotherapy.</p></caption>
<graphic alternate-form-of="table2-1078155212461289" xlink:href="10.1177_1078155212461289-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>No. of chemo cycle</th>
<th>Adverse effect(s)</th>
<th>Management plan</th></tr></thead>
<tbody align="left">
<tr>
<td>FOLFIRI C1</td>
<td rowspan="5">Uneventful</td>
<td align="left" rowspan="5">Dose of chemotherapeutic agents remained unadjusted</td></tr>
<tr>
<td>FOLFIRI C2</td></tr>
<tr>
<td>FOLFIRI C3</td></tr>
<tr>
<td>FOLFIRI C4</td></tr>
<tr>
<td>FOLFIRI C5 + Cetuximab C1</td></tr>
<tr>
<td>FOLFIRI C6 + Cetuximab C2</td>
<td/>
<td/></tr>
<tr>
<td>FOLFIRI C7 + Cetuximab C3</td>
<td align="justify">D3 post chemotherapy: 10 episodes of diarrhoea, (CTCAE Grade 4);</td>
<td align="justify">Hospitalized for hydration; discharged well</td></tr>
<tr>
<td/>
<td> 4 episodes of vomiting, (CTCAE  Grade 2)</td>
<td/></tr>
<tr>
<td>FOLFIRI C8 + Cetuximab C4</td>
<td align="justify">Presented with paronychia over finger nails on both hands and dry skin</td>
<td align="justify">D1: Dose reduction for Irinotecan (180 → 120 mg/m<sup>2</sup>) and Cetuximab (500 → 300 mg/m<sup>2</sup>).</td></tr>
<tr>
<td/>
<td/>
<td align="justify">D2: Chemotherapy was withheld completely.</td></tr>
<tr>
<td/>
<td/>
<td align="left">Discharged with PO Cloxacillin (500 mg QID) for a week; KMnO<sub>4</sub> antiseptic soak and Gentamicin cream</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1078155212461289"><p>C: cycle; KMnO<sub>4</sub>: potassium permanganate; NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>On examination, nail changes consisted of painful, erythematous, and edematous paronychial inflammation coupled with the development of pyogenic granuloma-like papules or periungual abscesses. The digits most notably affected were the thumbs as featured in <xref ref-type="fig" rid="fig1-1078155212461289">Figure 1(b)</xref>. The recent carcinoembryonic antigen (CEA) was not raised (&lt;0.5 ng/mL) and the latest computed tomography (CT) scan showed paraaortic and common illia lymph nodes. A combination of <italic>T. Unasyn®</italic> (Ampicillin/Sulbactam), Potassium permanganate (KMnO<sub>4</sub>) antiseptic soak and Gentamicin cream were prescribed by the dermatology team as secondary bacterial infection was suspected to be under way. Culture and biopsies were not performed. Due to the history of severe diarrhoea post-cycle-7 chemotherapy, the oncology team decided to reduce the dose of irinotecan and cetuximab as recommended by BCCA protocol summary.<sup><xref ref-type="bibr" rid="bibr7-1078155212461289">7</xref></sup> Chemotherapy went on well on day 1. However, she complained of abdominal pain following the ingestion of <italic>Unasyn®</italic> tablets. Following that, <italic>Unasyn®</italic> 375 mg twice daily was discontinued and was switched to C. Cloxacillin 500 mg four times daily for further treatment of paronychia. In the meantime, the oncology team decided to withhold chemotherapy in light of the side effects presumably to have been brought on by cetuximab, because she has no history of cutaneous reactions when she was treated with irinotecan (FOLFIRI) alone in the past. Upon <italic>Naranjo</italic> assessment, a score of five was obtained, suggesting <italic>probable</italic> drug-induced reaction. The paronychia and granulation of the fingers recovered gradually and completely by the third week following the discontinuation of chemotherapy and a week course of antibiotics.</p>
</sec>
<sec id="sec2-1078155212461289" sec-type="discussion"><title>Discussion</title>
<p>The most common cutaneous side-effect associated with the use of EGFR inhibitors is acneiform follicular eruption, which occurs in approximately 75–100% of patients.<sup><xref ref-type="bibr" rid="bibr8-1078155212461289">8</xref><xref ref-type="bibr" rid="bibr9-1078155212461289"/><xref ref-type="bibr" rid="bibr10-1078155212461289"/><xref ref-type="bibr" rid="bibr11-1078155212461289"/><xref ref-type="bibr" rid="bibr12-1078155212461289"/><xref ref-type="bibr" rid="bibr13-1078155212461289"/><xref ref-type="bibr" rid="bibr14-1078155212461289"/>–<xref ref-type="bibr" rid="bibr15-1078155212461289">15</xref></sup> On the same note, the incidence of EGFR inhibitor-induced paronychia have been reported in studies to range from 10% to 15%, with a median onset of 2 months following the initiation of therapy.<sup><xref ref-type="bibr" rid="bibr16-1078155212461289">16</xref><xref ref-type="bibr" rid="bibr17-1078155212461289"/>–<xref ref-type="bibr" rid="bibr18-1078155212461289">18</xref></sup> However, symptoms started to develop in our patient 6 weeks after the introduction of cetuximab into the chemotherapy regimen. The paronychial changes observed also showed much resemblance to those described previously with systemic retinoid and antiretroviral therapy.<sup><xref ref-type="bibr" rid="bibr19-1078155212461289">19</xref>,<xref ref-type="bibr" rid="bibr20-1078155212461289">20</xref></sup> Such changes could have been attributed to the thinned epidermis resultant aberrant epidermal keratinocytes maturation and increased rates of apoptosis observed histologically following the use of either EGFR inhibitors or systemic retinoids.<sup><xref ref-type="bibr" rid="bibr21-1078155212461289">21</xref><xref ref-type="bibr" rid="bibr22-1078155212461289"/><xref ref-type="bibr" rid="bibr23-1078155212461289"/><xref ref-type="bibr" rid="bibr24-1078155212461289"/>–<xref ref-type="bibr" rid="bibr25-1078155212461289">25</xref></sup> The consequential thinned and compact stratum corneum, therefore, may account for the greater predisposition to the initial piercing of or trauma to the periungual skin by the nail plate,<sup><xref ref-type="bibr" rid="bibr2-1078155212461289">2</xref></sup> which renders the nail folds to be vulnerable for inflammation and infection.</p>
<p>Nevertheless, the distribution of paronychial inflammation that was noted in our patient was inconsistent with that suggested in the literature which claims that great toenails are frequently involved.<sup><xref ref-type="bibr" rid="bibr26-1078155212461289">26</xref></sup> Such manifestation was noted only over the fingernails in our patient. Periungual abscesses and pyogenic granuloma developed also showed similarities to those described in some patients treated with cetuximab or gefitinib.<sup><xref ref-type="bibr" rid="bibr16-1078155212461289">16</xref>,<xref ref-type="bibr" rid="bibr17-1078155212461289">17</xref>,<xref ref-type="bibr" rid="bibr27-1078155212461289">27</xref><xref ref-type="bibr" rid="bibr28-1078155212461289"/><xref ref-type="bibr" rid="bibr29-1078155212461289"/><xref ref-type="bibr" rid="bibr30-1078155212461289"/>–<xref ref-type="bibr" rid="bibr31-1078155212461289">31</xref></sup> A recent study showed that a wide variety of Gram-positive and Gram-negative bacteria, as well as <italic>Candida albicans</italic>, may be cultured from nail lesions. The largest Gram-positive and negative bacteria isolated being coagulase-negative <italic>staphylococcus</italic> and <italic>Klebsiella</italic> species, respectively.<sup><xref ref-type="bibr" rid="bibr32-1078155212461289">32</xref></sup> These findings were in contrast to that reported by Busam et al.<sup><xref ref-type="bibr" rid="bibr16-1078155212461289">16</xref></sup> earlier which found that neither candida nor bacteria were cultured at the onset of the paronychial lesions. However, culture and sensitivity test was not performed in our patient and cloxacillin was started as an empirical treatment. As paronychia possesses a potential to become superinfected, culturing of skin lesions is recommended so that relevant antimicrobial agent could be targeted accordingly.<sup><xref ref-type="bibr" rid="bibr33-1078155212461289">33</xref></sup></p>
<p>Systemic antimicrobial agent such as doxycycline has been highly advocated by Suh et al.<sup><xref ref-type="bibr" rid="bibr31-1078155212461289">31</xref></sup> for the treatment of cetuximab-induced paronychia based on their relatively extensive clinical experience in treating acneiform EGFR inhibitor-induced eruption in their institution. Good responses following doxycycline treatment seen in two cases<sup><xref ref-type="bibr" rid="bibr31-1078155212461289">31</xref>,<xref ref-type="bibr" rid="bibr34-1078155212461289">34</xref></sup> (<xref ref-type="table" rid="table3-1078155212461289">Table 3</xref>) were believed to be attributed to its additional anti-inflammatory properties, which allow it to inhibit the matrix metalloproteinases (MMPs) and downregulate expression of proinflammatory cytokines (tumour necrosis factor-α, interleukin-1β).<sup><xref ref-type="bibr" rid="bibr35-1078155212461289">35</xref></sup> However, clinical unresponsiveness with doxycycline treatment has also been observed in some cases.<sup><xref ref-type="bibr" rid="bibr32-1078155212461289">32</xref></sup> Consequently, this had led to the latest recommendation of paronychia treatment with oral cephalosporin, such as cefuroxime, as it assures good cutaneous penetration and Gram-positive bacteria coverage.<sup><xref ref-type="bibr" rid="bibr32-1078155212461289">32</xref></sup> In cases where Gram-negative isolates predominate and cefuroxime is likely to be ineffective, oral fluoroquinolones such as ciprofloxacin, levofloxacin and moxifloxacin could be considered as they have wider spectrum of coverage, high tissue penetration and intracellular concentrations.<sup><xref ref-type="bibr" rid="bibr32-1078155212461289">32</xref></sup> Interestingly, a week course of cloxacillin along with gentamicin cream and potassium permanganate antiseptic soak brought almost complete alleviation of pain and inflammation over 3 weeks in our patient. This observation was contradictory to that seen in Busam’s studies<sup><xref ref-type="bibr" rid="bibr16-1078155212461289">16</xref></sup> as those suffered from paronychia cultured with <italic>Staphylococcus aureus</italic> did not respond to antistaphylococcal agent, instead, greatest relief was attained with soaks and cushioning. However, rapid recovery experienced in our patient could also be ascribed to the cessation of EGFR inhibitor therapy.
<table-wrap id="table3-1078155212461289" position="float"><label>Table 3.</label><caption><p>Published reports and summary of clinical characteristics of cetuximab-induced nail and periungual toxicities.</p></caption>
<graphic alternate-form-of="table3-1078155212461289" xlink:href="10.1177_1078155212461289-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Report</th>
<th>Concurrent folliculitis</th>
<th>Clinical features</th>
<th>Onset</th>
<th>Culture</th>
<th>Management</th>
<th>Course</th>
<th>Disease response or response to cetuximab</th></tr></thead>
<tbody align="left">
<tr>
<td>Busam, 2001<sup><xref ref-type="bibr" rid="bibr1-1078155212461289">1</xref><xref ref-type="bibr" rid="bibr6-1078155212461289">6</xref></sup> (<italic>N</italic> = 5/10)</td>
<td align="justify">Yes (10/10)</td>
<td align="justify">5/10: Swelling of lateral nail folds with friable pyogenic granuloma-like changes on fingers and toes</td>
<td align="justify">NR</td>
<td align="justify"><italic>Candida</italic> and bacterial cultures negative at onset; <italic>Staphylococcus aureus</italic> later (from ‘some’ lesions)</td>
<td align="justify">Soaks and cushioning; antibiotics for <italic>Staphylococcus aureus</italic></td>
<td align="justify">NR</td>
<td align="justify">NR</td></tr>
<tr>
<td>Boucher, 2002<sup><xref ref-type="bibr" rid="bibr2-1078155212461289">2</xref><xref ref-type="bibr" rid="bibr7-1078155212461289">7</xref></sup>(<italic>N</italic> = 1)</td>
<td align="justify">No</td>
<td align="justify">Edematous dusky red plaques and granulation tissue in periungual distribution on several fingers; toes not involved</td>
<td align="justify">4 weeks</td>
<td align="justify">Not done</td>
<td align="justify">Triamcinolone ointment; nystatin</td>
<td align="justify">Waxed and waned</td>
<td align="justify">Ineffective</td></tr>
<tr>
<td>Monti, 2003<sup><xref ref-type="bibr" rid="bibr30-1078155212461289">30</xref></sup> (<italic>N</italic> = 2)</td>
<td align="justify">Yes</td>
<td align="justify">Paronychia with pain, erythema, edema on fingers and toes</td>
<td align="justify">4 months</td>
<td align="justify">Not done</td>
<td align="justify">Aluminium chloride galenic gel</td>
<td align="justify">NR</td>
<td align="justify">NR</td></tr>
<tr>
<td>Suh, 2006<sup><xref ref-type="bibr" rid="bibr31-1078155212461289">31</xref></sup> (<italic>N</italic> = 1)</td>
<td align="justify">NR</td>
<td align="justify">Edema, erythema, tenderness in paronychium with onycholysis on fingers</td>
<td align="justify">6 months</td>
<td align="justify">Not done</td>
<td align="justify">Cetuximab stopped (bevacizumab continued); no improvement with mupirocin and cephalexin; doxycycline (100 mg BD for 6 weeks)</td>
<td align="justify">Improved in response to doxycycline</td>
<td align="justify">NR</td></tr>
<tr>
<td rowspan="3">Roé, 2006<sup><xref ref-type="bibr" rid="bibr3-1078155212461289">3</xref><xref ref-type="bibr" rid="bibr7-1078155212461289">7</xref></sup> (<italic>N</italic> = 5)</td>
<td rowspan="3">Yes (12/14)</td>
<td align="left" rowspan="3">5/14: Swelling of the lateral nailfolds and generally on the thumb or big toe</td>
<td rowspan="3">55 days</td>
<td rowspan="3">Not done</td>
<td align="justify" rowspan="3">Topical antibiotics (The specific type not reported)</td>
<td align="justify" rowspan="3">Most patients improved with topical antibiotics but one required minor surgery owing to the development of a pyogenic granuloma.</td>
<td align="justify">2/5 stable disease</td></tr>
<tr>
<td> 2/5 stopped cetuximab because of progression</td></tr>
<tr>
<td> 1/5 partial response</td></tr>
<tr>
<td>Ocvirk, 2010<sup><xref ref-type="bibr" rid="bibr18-1078155212461289">18</xref></sup> (<italic>N</italic> = 5)</td>
<td align="justify">Yes (31/31)</td>
<td align="justify">5/31: Nail changes</td>
<td align="justify">NR</td>
<td align="justify">Not done</td>
<td align="justify">Gentamicin ointment for 4–5 weeks</td>
<td align="justify">Partial improvement</td>
<td align="justify">NR</td></tr>
<tr>
<td>Tomková, 2010<sup><xref ref-type="bibr" rid="bibr3-1078155212461289">3</xref><xref ref-type="bibr" rid="bibr4-1078155212461289">4</xref></sup> (<italic>N</italic> = 1)</td>
<td align="justify">Yes (22/24)</td>
<td align="justify">1/24: Paronychia</td>
<td align="justify">NR</td>
<td align="justify">Not done</td>
<td align="justify">PO Doxycycline</td>
<td align="justify">Good response</td>
<td align="justify">Alive 10 months, stable disease</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1078155212461289"><p>NR: not reported.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Paronychia is becoming more rampant of late following the increasing utilization and development of EGFR inhibitors coupled with its widening indications in several solid tumour malignancies. In the preliminary stages of EGFR-induced paronychia, topical steroids,<sup><xref ref-type="bibr" rid="bibr27-1078155212461289">27</xref></sup> antiseptic soak<sup><xref ref-type="bibr" rid="bibr16-1078155212461289">16</xref></sup> or antibiotic ointments<sup><xref ref-type="bibr" rid="bibr18-1078155212461289">18</xref></sup> with appropriate dressings is recommended. The antiseptic treatment is advocated to be continued even after the systemic therapy has been initiated.<sup><xref ref-type="bibr" rid="bibr32-1078155212461289">32</xref></sup> Awareness of the side-effects by the dermatologist and oncologist is pertinent as lesions could be painful and have a profound impact on patients’ quality of life. In cases where paronychia is severe, improvement might even require discontinuation of EGFR inhibitor therapy. Hence, heightened awareness may ensure effective treatment of the cutaneous side-effects, thereby, facilitating patients’ compliance with EGFR inhibitor therapy which could then assure effective oncology management. On that note, pharmacist in multidisciplinary team should provide specific tools to promote patient self-awareness and assure early recognition of clinical sign and symptom of dermatologic toxicities associated with the use of EGFR inhibitor.<sup><xref ref-type="bibr" rid="bibr36-1078155212461289">36</xref></sup> Apart from specific recommendations, investigational pharmacotherapeutic agents are encouraged to be tested to overcome dermatologic toxicity like this as much of knowledge and recommendations for treating paronychia have only been gathered from previous experience or anecdotal reports. There are, as yet, no randomized controlled studies that have been carried out to evaluate therapies for paronychia.<sup><xref ref-type="bibr" rid="bibr36-1078155212461289">36</xref></sup></p>
</sec>
<sec id="sec3-1078155212461289" sec-type="conclusions"><title>Conclusion</title>
<p>The nail and periungual toxicities associated with the use of EGFR inhibitor therapy are a class phenomenon that develops in no less than four weeks following the initiation of therapy. A wide range of Gram-positive and Gram-negative bacteria as well as <italic>Candida</italic> species may be present in periungual lesions. In cases where infections are suspected, empirical oral antibiotics such as cephalosporins or fluoroquinolones may be warranted owing in part to its appealing pharmacokinetic property that permits attainment of high concentrations in the relevant tissues. In cases of mild to moderate severity, on the other hand, management with topical steroid or antibiotics along with antiseptic soak would suffice.</p>
</sec>
</body>
<back>
<sec id="sec4-1078155212461289"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-1078155212461289"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cowen</surname><given-names>E</given-names></name></person-group>. <article-title>Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy</article-title>. <source>J Am Acad Dermatol</source> <year>2007</year>; <volume>56</volume>: <fpage>514</fpage>–<lpage>517</lpage>.</citation></ref>
<ref id="bibr2-1078155212461289"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>LP</given-names></name></person-group>. <article-title>Nail toxicity associated with epidermal growth factor receptor inhibitor therapy</article-title>. <source>J Am Acad Dermatol</source> <year>2007</year>; <volume>56</volume>: <fpage>460</fpage>–<lpage>465</lpage>.</citation></ref>
<ref id="bibr3-1078155212461289"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacouture</surname><given-names>M</given-names></name></person-group>. <article-title>Mechanisms of cutaneous toxicities to EGFR inhibitors</article-title>. <source>Nat Rev</source> <year>2006</year>; <volume>6</volume>: <fpage>803</fpage>–<lpage>812</lpage>.</citation></ref>
<ref id="bibr4-1078155212461289"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>J</given-names></name><name><surname>Muhsin</surname><given-names>M</given-names></name><name><surname>Kirkpatrick</surname><given-names>P</given-names></name></person-group>. <article-title>Cetuximab</article-title>. <source>Nat Rev</source> <year>2004</year>; <volume>3</volume>: <fpage>549</fpage>–<lpage>550</lpage>.</citation></ref>
<ref id="bibr5-1078155212461289"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cutsem</surname><given-names>E</given-names></name><name><surname>Köhne</surname><given-names>C</given-names></name><name><surname>Hitre</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer</article-title>. <source>N Engl J Med</source> <year>2009</year>; <volume>360</volume>: <fpage>1408</fpage>–<lpage>1417</lpage>.</citation></ref>
<ref id="bibr6-1078155212461289"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cutsem</surname><given-names>E</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name></person-group>. <article-title>Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment</article-title>. <source>Ann Oncol</source> <year>2010</year>; <volume>21</volume>(<supplement>Suppl 5</supplement>): <fpage>v93</fpage>–<lpage>v97</lpage>.</citation></ref>
<ref id="bibr7-1078155212461289"><label>7</label><citation citation-type="other"><comment>BC Cancer Agency Protocol Summary UGIAVCETIR. BCCA Protocol Summary Third Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan, 2009; revised 2012</comment>.</citation></ref>
<ref id="bibr8-1078155212461289"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burtness</surname><given-names>B</given-names></name><name><surname>Goldwasser</surname><given-names>M</given-names></name><name><surname>Flood</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study</article-title>. <source>J Clin Oncol</source> <year>2005</year>; <volume>23</volume>: <fpage>8646</fpage>–<lpage>8654</lpage>.</citation></ref>
<ref id="bibr9-1078155212461289"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busam</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Granter</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas. [Abstract]</article-title>. <source>Mod Patho</source> <year>1999</year>; <volume>12</volume>: <fpage>786</fpage>–<lpage>793</lpage>.</citation></ref>
<ref id="bibr10-1078155212461289"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Humblet</surname><given-names>Y</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer</article-title>. <source>N Engl J Med</source> <year>2004</year>; <volume>351</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation></ref>
<ref id="bibr11-1078155212461289"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eames</surname><given-names>T</given-names></name><name><surname>Kroth</surname><given-names>J</given-names></name><name><surname>Flaig</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy</article-title>. <source>Acta Derm Venereol</source> <year>2010</year>; <volume>2</volume>: <fpage>202</fpage>–<lpage>203</lpage>.</citation></ref>
<ref id="bibr12-1078155212461289"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Sadeghi</surname><given-names>P</given-names></name><name><surname>Pinter-Brown</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management</article-title>. <source>J Am Acad Dermatol</source> <year>2007</year>; <volume>56</volume>: <fpage>317</fpage>–<lpage>326</lpage>.</citation></ref>
<ref id="bibr13-1078155212461289"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Molinari</surname><given-names>E</given-names></name><name><surname>De Quatrebarbes</surname><given-names>J</given-names></name><name><surname>André</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cetuximab-induced acne</article-title>. <source>Dermatology</source> <year>2005</year>; <volume>211</volume>: <fpage>330</fpage>–<lpage>333</lpage>.</citation></ref>
<ref id="bibr14-1078155212461289"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segaert</surname><given-names>S</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name></person-group>. <article-title>Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors</article-title>. <source>Ann Oncol</source> <year>2005</year>; <volume>16</volume>: <fpage>1425</fpage>–<lpage>1433</lpage>.</citation></ref>
<ref id="bibr15-1078155212461289"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wollenberg</surname><given-names>A</given-names></name><name><surname>Kroth</surname><given-names>J</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Cutaneous side effects of EGFR inhibitors–appearance and management [Abstract]</article-title>. <source>Dtsch Med Wochenschr</source> <year>2010</year>; <volume>135</volume>: <fpage>149</fpage>–<lpage>154</lpage>.</citation></ref>
<ref id="bibr16-1078155212461289"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busam</surname><given-names>K</given-names></name><name><surname>Capodieci</surname><given-names>P</given-names></name><name><surname>Motzer</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225</article-title>. <source>Br J Dermatol</source> <year>2001</year>; <volume>144</volume>: <fpage>1169</fpage>–<lpage>1176</lpage>.</citation></ref>
<ref id="bibr17-1078155212461289"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Seo</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor</article-title>. <source>Acta Derm Venereol</source> <year>2004</year>; <volume>84</volume>: <fpage>23</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr18-1078155212461289"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ocvirk</surname><given-names>J</given-names></name><name><surname>Cencelj</surname><given-names>S</given-names></name></person-group>. <article-title>Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2010</year>; <volume>4</volume>: <fpage>453</fpage>–<lpage>459</lpage>.</citation></ref>
<ref id="bibr19-1078155212461289"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>K</given-names></name><name><surname>Weinstein</surname><given-names>M</given-names></name></person-group>. <article-title>Pyogenic granulomas during isotretinoin therapy</article-title>. <source>J Dermatol</source> <year>2011</year>; <volume>5</volume>: <fpage>5</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr20-1078155212461289"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tosti</surname><given-names>A</given-names></name><name><surname>Piraccini</surname><given-names>B</given-names></name><name><surname>D'Antuono</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Paronychia associated with antiretroviral therapy</article-title>. <source>Br J Dermatol</source> <year>1999</year>; <volume>140</volume>: <fpage>1165</fpage>–<lpage>1168</lpage>.</citation></ref>
<ref id="bibr21-1078155212461289"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albanell</surname><given-names>J</given-names></name><name><surname>Rojo</surname><given-names>F</given-names></name><name><surname>Averbuch</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition</article-title>. <source>JCO</source> <year>2002</year>; <volume>20</volume>: <fpage>110</fpage>–<lpage>124</lpage>.</citation></ref>
<ref id="bibr22-1078155212461289"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baran</surname><given-names>R</given-names></name></person-group>. <article-title>Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects</article-title>. <source><italic>[Abstract].</italic> Clin Exp Dermatol</source> <year>1986</year>; <volume>11</volume>: <fpage>148</fpage>–<lpage>152</lpage>.</citation></ref>
<ref id="bibr23-1078155212461289"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapellier</surname><given-names>B</given-names></name><name><surname>Mark</surname><given-names>M</given-names></name><name><surname>Messaddeq</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled</article-title>. <source>EMBO J</source> <year>2002</year>; <volume>21</volume>: <fpage>3402</fpage>–<lpage>3413</lpage>.</citation></ref>
<ref id="bibr24-1078155212461289"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>G</given-names></name><name><surname>Voorhees</surname><given-names>J</given-names></name></person-group>. <article-title>Molecular mechanisms of retinoid actions in skin</article-title>. <source>FASEB J</source> <year>1996</year>; <volume>10</volume>: <fpage>1002</fpage>–<lpage>1013</lpage>.</citation></ref>
<ref id="bibr25-1078155212461289"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Doorn</surname><given-names>R</given-names></name><name><surname>Kirtschig</surname><given-names>G</given-names></name><name><surname>Scheffer</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor</article-title>. <source>Br J Dermatol</source> <year>2002</year>; <volume>147</volume>: <fpage>598</fpage>–<lpage>601</lpage>.</citation></ref>
<ref id="bibr26-1078155212461289"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehmann</surname><given-names>L</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Wollenberg</surname><given-names>A</given-names></name></person-group>. <article-title>Cutaneous side-effects of EGFR inhibitors and their management</article-title>. <source>Skin Therapy Letter</source> <year>2011</year>; <volume>16</volume>: <fpage>1</fpage>–<lpage>1</lpage>.</citation></ref>
<ref id="bibr27-1078155212461289"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>K</given-names></name><name><surname>Davidson</surname><given-names>K</given-names></name><name><surname>Mirakhur</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody</article-title>. <source>J Am Acad Dermatol</source> <year>2002</year>; <volume>47</volume>: <fpage>632</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr28-1078155212461289"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source> <year>2004</year>; <volume>22</volume>: <fpage>4646</fpage>–<lpage>4648</lpage>.</citation></ref>
<ref id="bibr29-1078155212461289"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dainichi</surname><given-names>T</given-names></name><name><surname>Tanakaa</surname><given-names>M</given-names></name><name><surname>Tsurutab</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor</article-title>. <source>Dermatology</source> <year>2003</year>; <volume>207</volume>: <fpage>324</fpage>–<lpage>325</lpage>.</citation></ref>
<ref id="bibr30-1078155212461289"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monti</surname><given-names>M</given-names></name><name><surname>Mancini</surname><given-names>L</given-names></name><name><surname>Ferrari</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Complications of therapy and a diagnostic dilemma case, case 2: cutaneous toxicity induced by cetuximab</article-title>. <source>J Clin Oncol</source> <year>2003</year>; <volume>21</volume>: <fpage>4651</fpage>–<lpage>4653</lpage>.</citation></ref>
<ref id="bibr31-1078155212461289"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>K-Y</given-names></name><name><surname>Kindler</surname><given-names>H</given-names></name></person-group>. <article-title>Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab</article-title>. <source>Br J Dermatol</source> <year>2006</year>; <volume>154</volume>: <fpage>191</fpage>–<lpage>192</lpage>.</citation></ref>
<ref id="bibr32-1078155212461289"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eames</surname><given-names>T</given-names></name><name><surname>Grabein</surname><given-names>B</given-names></name><name><surname>Kroth</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2010</year>; <volume>24</volume>: <fpage>958</fpage>–<lpage>960</lpage>.</citation></ref>
<ref id="bibr33-1078155212461289"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sassone</surname><given-names>L</given-names></name><name><surname>Fidel</surname><given-names>R</given-names></name><name><surname>Murad</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests</article-title>. <source>Aust Endod J</source> <year>2008</year>; <volume>34</volume>: <fpage>19</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr34-1078155212461289"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomková</surname><given-names>H</given-names></name><name><surname>Kohoutek</surname><given-names>M</given-names></name><name><surname>Zábojníková</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cetuximab-induced cutaneous toxicity</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2010</year>; <volume>24</volume>: <fpage>692</fpage>–<lpage>696</lpage>.</citation></ref>
<ref id="bibr35-1078155212461289"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms</article-title>. <source>Adv Dent Res</source> <year>1998</year>; <volume>12</volume>: <fpage>12</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr36-1078155212461289"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacouture</surname><given-names>M</given-names></name><name><surname>Anadkat</surname><given-names>M</given-names></name><name><surname>Bensadoun</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities</article-title>. <source>Support Care Cancer</source> <year>2011</year>; <volume>19</volume>: <fpage>1079</fpage>–<lpage>1095</lpage>.</citation></ref>
<ref id="bibr37-1078155212461289"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roé</surname><given-names>E</given-names></name><name><surname>García Muret</surname><given-names>M</given-names></name><name><surname>Marcuello</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients</article-title>. <source>J Am Acad Dermatol</source> <year>2006</year>; <volume>55</volume>: <fpage>429</fpage>–<lpage>437</lpage>.</citation></ref>
</ref-list>
</back>
</article>